Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice

Connie Cheung, Aiming Yu, Chong Sheng Chen, Kristopher W. Krausz, Linda G. Byrd, Lionel Feigenbaum, Robert J. Edwards, David J. Waxman, Frank J. Gonzalez

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

The impact of age and sex on the expression of hepatic cytochrome P450 3A4 (CYP3A4) was recently determined in a transgenic mouse line carrying the human CYP3A4 gene. To further investigate the physiological regulation of human CYP3A genes, a novel transgenic mouse line was generated using a bacterial artificial chromosome clone containing both CYP3A4 and CYP3A7 genes. CYP3A7 expression was observed in transgenic mouse fetal livers, whereas CYP3A4 exhibited developmental expression characterized by sexual dimorphism in postpubertal livers. Hepatic CYP3A4 protein and RNA were expressed in immature transgenic male mice and became undetectable after 6 weeks of age, whereas CYP3A4 was expressed in both immature and adult females. CYP3A4 was markedly elevated by the xenobiotic receptor activator phenobarbital in both male and female livers, demonstrating drug induction of the CYP3A4 transgene in this mouse model. Furthermore, continuous infusion of recombinant growth hormone (GH) in transgenic male mice, overriding the pulsatile male plasma GH profile, increased hepatic CYP3A4 mRNA and protein to normal female levels. Continuous GH treatment also feminized the expression of endogenous murine Cyp2b and Cyp3a44 genes. Thus, human CYP3A4 contains all of the gene regulatory sequences required for it to respond to endogenous hormonal regulators of developmental expression and sexual dimorphism, in particular GH. These findings may help elucidate the role of GH in determining the sex-dependent expression of CYP3A4 in human liver and suggest that GH therapy may alter the pharmacokinetic and pharmacodynamic properties of CYP3A4 substrates, leading to enhanced metabolism and disposition of drugs in men.

Original languageEnglish (US)
Pages (from-to)1328-1334
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume316
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Sex Characteristics
Transgenic Mice
Growth Hormone
Liver
Genes
Bacterial Artificial Chromosomes
Xenobiotics
Regulator Genes
Transgenes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. / Cheung, Connie; Yu, Aiming; Chen, Chong Sheng; Krausz, Kristopher W.; Byrd, Linda G.; Feigenbaum, Lionel; Edwards, Robert J.; Waxman, David J.; Gonzalez, Frank J.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 316, No. 3, 03.2006, p. 1328-1334.

Research output: Contribution to journalArticle

Cheung, C, Yu, A, Chen, CS, Krausz, KW, Byrd, LG, Feigenbaum, L, Edwards, RJ, Waxman, DJ & Gonzalez, FJ 2006, 'Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice', Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 1328-1334. https://doi.org/10.1124/jpet.105.094367
Cheung, Connie ; Yu, Aiming ; Chen, Chong Sheng ; Krausz, Kristopher W. ; Byrd, Linda G. ; Feigenbaum, Lionel ; Edwards, Robert J. ; Waxman, David J. ; Gonzalez, Frank J. / Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 316, No. 3. pp. 1328-1334.
@article{936de6c659f34b35a17b9ba98cd68875,
title = "Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice",
abstract = "The impact of age and sex on the expression of hepatic cytochrome P450 3A4 (CYP3A4) was recently determined in a transgenic mouse line carrying the human CYP3A4 gene. To further investigate the physiological regulation of human CYP3A genes, a novel transgenic mouse line was generated using a bacterial artificial chromosome clone containing both CYP3A4 and CYP3A7 genes. CYP3A7 expression was observed in transgenic mouse fetal livers, whereas CYP3A4 exhibited developmental expression characterized by sexual dimorphism in postpubertal livers. Hepatic CYP3A4 protein and RNA were expressed in immature transgenic male mice and became undetectable after 6 weeks of age, whereas CYP3A4 was expressed in both immature and adult females. CYP3A4 was markedly elevated by the xenobiotic receptor activator phenobarbital in both male and female livers, demonstrating drug induction of the CYP3A4 transgene in this mouse model. Furthermore, continuous infusion of recombinant growth hormone (GH) in transgenic male mice, overriding the pulsatile male plasma GH profile, increased hepatic CYP3A4 mRNA and protein to normal female levels. Continuous GH treatment also feminized the expression of endogenous murine Cyp2b and Cyp3a44 genes. Thus, human CYP3A4 contains all of the gene regulatory sequences required for it to respond to endogenous hormonal regulators of developmental expression and sexual dimorphism, in particular GH. These findings may help elucidate the role of GH in determining the sex-dependent expression of CYP3A4 in human liver and suggest that GH therapy may alter the pharmacokinetic and pharmacodynamic properties of CYP3A4 substrates, leading to enhanced metabolism and disposition of drugs in men.",
author = "Connie Cheung and Aiming Yu and Chen, {Chong Sheng} and Krausz, {Kristopher W.} and Byrd, {Linda G.} and Lionel Feigenbaum and Edwards, {Robert J.} and Waxman, {David J.} and Gonzalez, {Frank J.}",
year = "2006",
month = "3",
doi = "10.1124/jpet.105.094367",
language = "English (US)",
volume = "316",
pages = "1328--1334",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice

AU - Cheung, Connie

AU - Yu, Aiming

AU - Chen, Chong Sheng

AU - Krausz, Kristopher W.

AU - Byrd, Linda G.

AU - Feigenbaum, Lionel

AU - Edwards, Robert J.

AU - Waxman, David J.

AU - Gonzalez, Frank J.

PY - 2006/3

Y1 - 2006/3

N2 - The impact of age and sex on the expression of hepatic cytochrome P450 3A4 (CYP3A4) was recently determined in a transgenic mouse line carrying the human CYP3A4 gene. To further investigate the physiological regulation of human CYP3A genes, a novel transgenic mouse line was generated using a bacterial artificial chromosome clone containing both CYP3A4 and CYP3A7 genes. CYP3A7 expression was observed in transgenic mouse fetal livers, whereas CYP3A4 exhibited developmental expression characterized by sexual dimorphism in postpubertal livers. Hepatic CYP3A4 protein and RNA were expressed in immature transgenic male mice and became undetectable after 6 weeks of age, whereas CYP3A4 was expressed in both immature and adult females. CYP3A4 was markedly elevated by the xenobiotic receptor activator phenobarbital in both male and female livers, demonstrating drug induction of the CYP3A4 transgene in this mouse model. Furthermore, continuous infusion of recombinant growth hormone (GH) in transgenic male mice, overriding the pulsatile male plasma GH profile, increased hepatic CYP3A4 mRNA and protein to normal female levels. Continuous GH treatment also feminized the expression of endogenous murine Cyp2b and Cyp3a44 genes. Thus, human CYP3A4 contains all of the gene regulatory sequences required for it to respond to endogenous hormonal regulators of developmental expression and sexual dimorphism, in particular GH. These findings may help elucidate the role of GH in determining the sex-dependent expression of CYP3A4 in human liver and suggest that GH therapy may alter the pharmacokinetic and pharmacodynamic properties of CYP3A4 substrates, leading to enhanced metabolism and disposition of drugs in men.

AB - The impact of age and sex on the expression of hepatic cytochrome P450 3A4 (CYP3A4) was recently determined in a transgenic mouse line carrying the human CYP3A4 gene. To further investigate the physiological regulation of human CYP3A genes, a novel transgenic mouse line was generated using a bacterial artificial chromosome clone containing both CYP3A4 and CYP3A7 genes. CYP3A7 expression was observed in transgenic mouse fetal livers, whereas CYP3A4 exhibited developmental expression characterized by sexual dimorphism in postpubertal livers. Hepatic CYP3A4 protein and RNA were expressed in immature transgenic male mice and became undetectable after 6 weeks of age, whereas CYP3A4 was expressed in both immature and adult females. CYP3A4 was markedly elevated by the xenobiotic receptor activator phenobarbital in both male and female livers, demonstrating drug induction of the CYP3A4 transgene in this mouse model. Furthermore, continuous infusion of recombinant growth hormone (GH) in transgenic male mice, overriding the pulsatile male plasma GH profile, increased hepatic CYP3A4 mRNA and protein to normal female levels. Continuous GH treatment also feminized the expression of endogenous murine Cyp2b and Cyp3a44 genes. Thus, human CYP3A4 contains all of the gene regulatory sequences required for it to respond to endogenous hormonal regulators of developmental expression and sexual dimorphism, in particular GH. These findings may help elucidate the role of GH in determining the sex-dependent expression of CYP3A4 in human liver and suggest that GH therapy may alter the pharmacokinetic and pharmacodynamic properties of CYP3A4 substrates, leading to enhanced metabolism and disposition of drugs in men.

UR - http://www.scopus.com/inward/record.url?scp=33644751822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644751822&partnerID=8YFLogxK

U2 - 10.1124/jpet.105.094367

DO - 10.1124/jpet.105.094367

M3 - Article

VL - 316

SP - 1328

EP - 1334

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -